833474-06-9

Basic information

• Product Name: 3-FORMYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 3-FORMYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER;N-Boc-3-morpholinecarbaldehyde;(S)-3-Formyl-morpholine-4-carboxylicacidtert-butylester;4-Boc-3-morpholinecarbaldehyde;4-Boc-3-formyl-morpholine
• CAS NO: 833474-06-9
• Molecular Formula: C₁₀H₁₇NO₄
• Molecular Weight: 215.25
• Mol File: 833474-06-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 308.977 °C at 760 mmHg
• Flash Point: 140.665 °C
• Appearance: /
• Density: 1.181 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.516
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 3-FORMYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FORMYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(833474-06-9)
• EPA Substance Registry System: 3-FORMYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(833474-06-9)

Safety Data

• Hazardous Substances Data: 833474-06-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H17NO4/c1-10(2,3)15-9(13)11-4-5-14-7-8(11)6-12/h6,8H,4-5,7H2,1-3H3

Upstream product

• 212650-43-6 4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid 
• 473923-56-7 tert-Butyl 3-(hydroxymethyl)-4-morpholinecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 106910-79-6 (RS)-4-benzyl-5-oxomorpholine-3-carboxylic acid 
• 106910-83-2 (rac)-3-hydroxymethylmorpholine 
• 110167-20-9 4-benzyl-3-(hydroxymethyl)morpholine 

Downstream Products

• 877078-82-5 tert-butyl 3-((1S,2S)-2-(3,5-difluorobenzyl)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-1-hydroxy-3-oxopropyl)morpholine-4-carboxylate 
• 910447-70-0 tert-butyl 3-((1S,2S)-2-(3,5-difluorobenzyl)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-1-hydroxy-3-oxopropyl)morpholine-4-carboxylate 
• 885274-05-5 3-(4-(tert-butoxycarbonyl)morpholin-3-yl)propanoic acid 

Relevant articles and documents

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. (I)

ARYL-SULFONAMIDE AND ARYL-SULFONE DERIVATIVES AS TRPML MODULATORS

The new arylsulfonamide and arylsulfone derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities and lysosome functions such as acid-related disorders and cancer.

FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of 5,6-dihydro-l,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of b.enefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.